Drugs for Methane Production (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Neomycin |
Approved, Vet_approved |
Early Phase 1 |
|
1404-04-2 |
8378 |
Synonyms:
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
11025-81-3
119-04-0
1393-86-8
1404-04-2
1405-10-3 (sulfate (salt))
4-18-00-07476 (Beilstein Handbook Reference)
72131_FLUKA
AB00443887
AC1L1QVH
Actilin
Actiline
Antibiotic 10676
Antibiotic produced by Streptomyces decaris. Neomycin B
Antibiotique
BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG
BDG-(1-4)NEB-(5-1)RIB-(3-1)NED
Biosol
BPBio1_000326
BRN 0101621
BSPBio_000296
Bykomycin
C01737
C23H46N6O13
C25H50N6O13
Caswell no. 595
Caswell No. 595
CCRIS 5462
CHEBI:7508
CID8378
D05140
DB00452
DB00994
D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
EINECS 204-292-2
EINECS 215-766-3
Endomixin
Enterfram
EPA Pesticide Chemical Code 006303
Fradiomycin
Fradiomycin b
Fradiomycin B
Fradiomycin sulfate
Fradiomycin Sulfate
Fradiomycinum
Framicetina
Framicetina [INN-Spanish]
Framycetin
Framycetin (INN)
Framycetin [INN:BAN:DCF]
Framycetin sulfate
Framycetine
Framycetine [INN-French]
Framycetinum
Framycetinum [INN-Latin]
Framygen
Fraquinol
FRM
HMS2089P15
HSDB 3242
Kaomycine
Lidamycin Creme
LS-96091
|
LS-96095
MolPort-003-938-736
Myacine
Myacyne
Mycifradin
Mycifradin-N
Myciguent
N1142_SIGMA
NCGC00179612-01
Neobiotic
Neobrettin
Neofracin
Neo-Fradin
Neolate
Neo-Mantle Creme
Neomas
Neomcin
Neomicina
Neomicina [DCIT]
Neomin
Neomix
neomycin
Neomycin
NEOMYCIN AND POLYMYXIN B SULFATES
Neomycin b
NEOMYCIN B
Neomycin b sulfate
Neomycin B sulfate
Neomycin B Sulfate
Neomycin palmitate
Neomycin solution
Neomycin sulfate
Neomycin Sulfate
NEOMYCIN SULFATE
Neomycin sulphate
Neomycin Sulphate
Neomycin trisulfate salt hydrate
Neomycine
Neomycine [INN-French]
Neomycinum
Neomycinum [INN-Latin]
Neo-Rx
Neosulf
Nivemycin
NMY
Palmitate, neomycin
PIMAVECORT
Prestwick3_000158
Soframycin
Soframycin Ophthalmic
Soframycine
ST075177
Sulfate, fradiomycin
Sulfate, framycetin
Sulfate, neomycin
Sulfate, neomycin b
Tuttomycin
UNII-4BOC774388
UNII-I16QD7X297
USAF CB-19
Vonamycin
VONAMYCIN
Vonamycin powder V
Vonamycin Powder V
|
|
2 |
|
Rifaximin |
Approved, Investigational |
Early Phase 1 |
|
80621-81-4 |
6436173 46783403 |
Synonyms:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate
(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,23,36-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6-oxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1,.0,.0,.0,]heptatriaconta-1(35),2,4,9,19,21,23,25(36),26(34),28,30,32-dodecaen-13-yl acetic acid
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV
80621-81-4
88747-56-2
AC-19112
alpha-0817185
Bio-0556
BRN 3584528
C43H51N3O11
CHEMBL1617
D02554
DB01220
Fatroximin
Flonorm
L 105
L 105 (Ansamacrolide antibiotic)
L 105SV
Lormyx
LS-178059
LS-64147
Lumenax
MLS000759430
Normix
Redactiv
|
RedActiv
Rifacol
Rifamixin
Rifamycin L 105
Rifamycin L 105SV
Rifaxidin
Rifaximin
Rifaximin (USAN/INN)
Rifaximin [USAN:INN]
Rifaximina
Rifaximina [Spanish]
Rifaximine
Rifaximine [French]
Rifaximinum
Rifaximinum [Latin]
Rifaximinun
Rifaxin
Ritacol
S1790_Selleck
SMR000466324
Spiraxin
UNII-L36O5T016N
Xifaxan
Xifaxan, Rifacol, Fatroximin, Rifaximin
Xifaxsan
Xifaxsan (TN)
|
|
3 |
|
Gastrointestinal Agents |
|
Early Phase 1 |
|
|
|
4 |
|
Anti-Infective Agents |
|
Early Phase 1 |
|
|
|
5 |
|
Anti-Bacterial Agents |
|
Early Phase 1 |
|
|
|
Interventional clinical trials:
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared With Placebo on Breath Methane Production in Breath Methane-Positive Subjects With IBS-C |
Completed |
NCT02495623 |
Phase 2 |
SYN-010 21 mg;SYN-010 42 mg;Placebo |
2 |
Methane Production and Glycemic Regulation in Pre-diabetic Subjects: Role of Methane in Glycemic Control |
Completed |
NCT01638429 |
Early Phase 1 |
Neomycin;Rifaximin |
|